Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10249-10261

  Han, Li Li ^a   Lv, Yi ^a   Guo, Hui ^a   Ruan, Zhi Ping ^a   Nan, Ke Jun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Biomarkers; Hepatocellular carcinoma; MicroRNAs; Pathogenesis; Targeted therapy

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BRIVANIB; CEDIRANIB; FAS ANTIGEN; GLYPICAN 3; LINIFANIB; MESSENGER RNA; MICRORNA; MICRORNA 122; MICRORNA 21; MICRORNA 221; MICRORNA 31; MICRORNA 34A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER PROGNOSIS; CHEMOSENSITIVITY; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; GENE REPLACEMENT THERAPY; HEPATITIS C; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; ANIMAL; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; EARLY DIAGNOSIS; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; EARLY DETECTION OF CANCER; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84920586200     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10249     Document Type: Article

References (137)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855]
2. He G, Karin M. NF-κB and STAT3 -key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168 [PMID: 21187858 DOI: 10.1038/cr.2010.183]
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432]
4. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: Recent advances. J Gastroenterol Hepatol 2011; 26 Suppl 1: 123-130 [PMID: 21199523 DOI: 10.1111/j.1440-1746.2010.06541.x]
5. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138: 493-502 [PMID: 19852963 DOI: 10.1053/j.gastro.2009.10.031]
6. Chen L, Ho DW, Lee NP, Sun S, Lam B, Wong KF, Yi X, Lau GK, Ng EW, Poon TC, Lai PB, Cai Z, Peng J, Leng X, Poon RT, Luk JM. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 2010; 17: 2518-2525 [PMID: 20354800 DOI: 10.1245/s10434-010-1038-8]
7. Wang L, Huang J, Jiang M, Zheng X. AFP computational secreted network construction and analysis between human hepatocellular carcinoma (HCC) and no-tumor hepatitis/cirrhotic liver tissues. Tumour Biol 2010; 31: 417-425 [PMID: 20532728 DOI: 10.1007/s13277-010-0050-8]
8. Kaleta EJ, Tolan NV, Ness KA, O'Kane D, Algeciras-Schimnich A. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Clin Biochem 2013; 46: 814-818 [PMID: 23454392]
9. Ducher A, Armelle A, Renaud A, Chloe O. Protein of human adenovirus inhibits the overall activation of the target of type I interferons by preventing mono-ubiquitantion of histone 2B. Irologie 2013; 17: 300-301
10. Zhang KJ, Qian J, Wang SB, Yang Y. Targeting Gene-Viro-Therapy with AFP driving Apoptin gene shows potent antitumor effect in hepatocarcinoma. J Biomed Sci 2012; 19: 20 [PMID: 22321574 DOI: 10.1186/1423-0127-19-20]
11. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254 [PMID: 16024626]
12. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miy-oshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97 [PMID: 12851874]
13. Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study. Acta Histochem 2012; 114: 547-552 [PMID: 22119409 DOI: 10.1016/j.acthis.2011.10.003]
14. Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, Huang Y, Li J, Wang Y, Gao Y, Han T, Du Z. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol 2012; 137: 937-945 [PMID: 22586053 DOI: 10.1309/AJCP0KZZ5DSIGMNY]
15. Wang FH, Yip YC, Zhang M, Vong HT, Chan KI, Wai KC, Wen JM. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol 2010; 63: 599-603 [PMID: 20501450 DOI: 10.1136/jcp.2010.075374]
16. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192-1205 [PMID: 22682243 DOI: 10.1016/j.cell.2012.05.012]
17. White BD, Chien AJ, Dawson DW. Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers. Gastroenterology 2012; 142: 219-232 [PMID: 22155636 DOI: 10.1053/j.gastro.2011.12.001]
18. Liu H, Li P, Zhai Y, Qu CF, Zhang LJ, Tan YF, Li N, Ding HG. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010; 16: 4410-4415 [PMID: 20845507]
19. Li L, Jin R, Zhang X, Lv F, Liu L, Liu D, Liu K, Li N, Chen D. Oncogenic activation of glypican-3 by c-Myc in human hepatocellular carcinoma. Hepatology 2012; 56: 1380-1390 [PMID: 22706665 DOI: 10.1002/hep.25891]
20. Gauglhofer C, Sagmeister S, Schrottmaier W, Fischer C, Rodgarkia-Dara C, Mohr T, Stättner S, Bichler C, Kandioler D, Wrba F, Schulte-Hermann R, Holzmann K, Grusch M, Marian B, Berger W, Grasl-Kraupp B. Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011; 53: 854-864 [PMID: 21319186 DOI: 10.1002/hep.24099]
21. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2013; 19: 920-928 [PMID: 23362325 DOI: 10.1158/1078-0432.CCR-12-2616]
22. Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 2010; 126: 1291-1301 [PMID: 19816934 DOI: 10.1002/ijc.24941]
23. Feng M, Kim H, Phung Y, Ho M. Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer 2011; 128: 2246-2247 [PMID: 20617511 DOI: 10.1002/ijc.25549]
24. El Bassiouny AE, El-Bassiouni NE, Nosseir MM, Zoheiry MM, El-Ahwany EG, Salah F, Omran ZS, Ibrahim RA. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med 2008; 10: 130 [PMID: 18679533]
25. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230 [PMID: 7595193]
26. Bortolami M, Kotsafti A, Cardin R, Farinati F. Fas /FasL system, IL-1beta expression and apoptosis in chronic HBV and HCV liver disease. J Viral Hepat 2008; 15: 515-522 [PMID: 18331250 DOI: 10.1111/j.1365-2893.2008.00974.x]
27. Hammam O, Mahmoud O, Zahran M, Aly S, Hosny K, Helmy A, Anas A. The role of fas/fas ligand system in the pathogenesis of liver cirrhosis and hepatocellular carcinoma. Hepat Mon 2012; 12: e6132 [PMID: 23300494 DOI: 10.5812/hepatmon.6132]
28. Pryczynicz A, Guzińska-Ustymowicz K, Kemona A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem Cytobiol 2010; 48: 425-429 [PMID: 21071349 DOI: 10.2478/v10042-010-0058-3]
29. García-Santos G, Martin V, Rodríguez-Blanco J, Herrera F, Casado-Zapico S, Sánchez-Sánchez AM, Antolín I, Rodríguez C. Fas/Fas ligand regulation mediates cell death in human Ewing's sarcoma cells treated with melatonin. Br J Cancer 2012; 106: 1288-1296 [PMID: 22382690 DOI: 10.1038/bjc.2012.66]
30. Huang X, Lu Z, Lv Z, Yu T, Yang P, Shen Y, Ding Y, Fu D, Zhang X, Fu Q, Yu Y. The Fas/Fas ligand death receptor pathway contributes to phenylalanine-induced apoptosis in cortical neurons. PLoS One 2013; 8: e71553 [PMID: 23940767]
31. Heldin CH, Landström M, Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 2009; 21: 166-176 [PMID: 19237272 DOI: 10.1016/j.ceb]
32. Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer. Cancer Detect Prev 2007; 31: 35-44 [PMID: 17293059]
33. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-520 [PMID: 19195051]
34. Sánchez A, Fabregat I. Growth factor-and cytokine-driven pathways governing liver stemness and differentiation. World J Gastroenterol 2010; 16: 5148-5161 [PMID: 21049549 DOI: 10.3748/wjg.v16.i41.5148]
35. Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415-424 [PMID: 20495575 DOI: 10.1038/nrc2853]
36. Hough C, Radu M, Doré JJ. Tgf-beta induced Erk phosphorylation of smad linker region regulates smad signaling. PLoS One 2012; 7: e42513 [PMID: 22880011 DOI: 10.1371/journal. pone.0042513]
37. Carmona-Cuenca I, Roncero C, Sancho P, Caja L, Fausto N, Fernández M, Fabregat I. Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity. J Hepatol 2008; 49: 965-976 [PMID: 18845355 DOI: 10.1016/j.jhep.2008.07.021]
38. Caja L, Sancho P, Bertran E, Iglesias-Serret D, Gil J, Fabregat I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-{beta}-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res 2009; 69: 7595-7602 [PMID: 19773433 DOI: 10.1158/0008-5472.CAN-09-1482]
39. Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 2008; 47: 1557-1566 [PMID: 18318443 DOI: 10.1002/hep.22201]
40. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985 [PMID: 6823562]
41. el-Houseini ME, Mohammed MS, Elshemey WM, Hussein TD, Desouky OS, Elsayed AA. Enhanced detection of hepatocellular carcinoma. Cancer Control 2005; 12: 248-253 [PMID: 16258497]
42. Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, Sun HC. Prognostic roles of cross-talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS One 2013; 8: e64598 [PMID: 23737988 DOI: 10.1371/journal. pone.0064598]
43. Llovet JM, Peña CE, Lathia CD, Shan M, Meinhardt G, Bruix J. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2290-2300 [PMID: 22374331 DOI: 10.1158/1078-0432]
44. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8: 292-301 [PMID: 21386818 DOI: 10.1038/nrclinonc]
45. Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a largescale multicenter study of 222 patients. Ann Oncol 2013; 24: 1786-1792 [PMID: 23508822 DOI: 10.1093/annonc/mdt072]
46. Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 2010; 15: 1198-1204 [PMID: 21036880 DOI: 10.1634/theoncologist]
47. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011; 2: 122-134 [PMID: 21399234]
48. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
49. Hsu C, Shen YC, Cheng CC, Hu FC, Cheng AL. Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials 2010; 31: 55-61 [PMID: 19737631 DOI: 10.1016/j.cct]
50. Hsu CH, Yang TS, Hsu C, Toh HC, Epstein RJ, Hsiao LT, Chen PJ, Lin ZZ, Chao TY, Cheng AL. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010; 102: 981-986 [PMID: 20160718 DOI: 10.1038/sj.bjc.6605580]
51. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS, Rafii S, Schwartz JD. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998 [PMID: 18565886]
52. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010; 11: 1943-1955 [PMID: 20586710 DOI: 10.1517/14656566]
53. Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kovàcs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist 2010; 15: 285-292 [PMID: 20203173]
54. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937]
55. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983 [PMID: 21349999 DOI: 10.1158/1078-0432. CCR-10-2011]
56. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-2098 [PMID: 22238246]
57. Toh HC, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 2013; 119: 380-387 [PMID: 22833179 DOI: 10.1002/cncr.27758]
58. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19: 6614-6623 [PMID: 24088738]
59. Alberts SR, Fitch TR, Kim GP, Morlan BW, Dakhil SR, Gross HM, Nair S. Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial. Am J Clin Oncol 2012; 35: 329-333 [PMID: 21422991]
60. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011; 17: 6914-6923 [PMID: 21831954]
61. Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, Obi S, Kondo Y, Taniguchi M, Tagawa K, Ikeda M, Morizane C, Okusaka T, Arioka H, Shiina S, Omata M. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67: 315-324 [PMID: 20390419 DOI: 10.1007/s00280-010-1320-2]
62. Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for Second-line Treatment of Advanced Hepatocellular Cancer: A Brown University Oncology Group Phase II Study. Am J Clin Oncol 2013; Epub ahead of print [PMID: 23648434]
63. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 2011; 17: 2528-2537 [PMID: 21372218 DOI: 10.1158/1078-0432.CCR-10-2638]
64. Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem 2013; 288: 4035-4047 [PMID: 23212913 DOI: 10.1074/jbc.M112.410506]
65. Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, Roggendorf M, Lu M. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011; 53: 1476-1485 [PMID: 21520166 DOI: 10.1002/hep.24195]
66. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO, Wong CM. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56: 622-631 [PMID: 22370893 DOI: 10.1002/hep.25679.Epub]
67. Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, Wang Z, Ding G, Zhuang SM, Zheng L, Tao W, Cao X. MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma. J Biol Chem 2011; 286: 36677-36685 [PMID: 21878637 DOI: 10.1074/jbc.M111.270561]
68. Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH, Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, Kung HF, Xie D. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut 2012; 61: 278-289 [PMID: 21672940 DOI: 10.1136/gut.2011.239145]
69. Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng IO. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by downregulating Rho-kinase 2. Gastroenterology 2011; 140: 322-331 [PMID: 20951699 DOI: 10.1053/j.gastro.2010.10.006]
70. Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, Lou J, Zhang W. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep 2012; 27: 1865-1872 [PMID: 22378186 DOI: 10.3892/or.2012.1701]
71. Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, Han J. Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients. J Gastroenterol Hepatol 2011; 26: 1630-1637 [PMID: 21557766 DOI: 10.1111/j.1440-1746]
72. Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int 2012; 32: 772-782 [PMID: 22429613]
73. Liu S, Guo W, Shi J, Li N, Yu X, Xue J, Fu X, Chu K, Lu C, Zhao J, Xie D, Wu M, Cheng S, Liu S. MicroRNA-135a contributes to the development of portal vein tumor thrombus by promoting metastasis in hepatocellular carcinoma. J Hepatol 2012; 56: 389-396 [PMID: 21888875]
74. Han ZB, Chen HY, Fan JW, Wu JY, Tang HM, Peng ZH. Upregulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation. J Cancer Res Clin Oncol 2012; 138: 153-161 [PMID: 22071603 DOI: 10.1007/s00432-011-]
75. Wang J, Li J, Shen J, Wang C, Yang L, Zhang X. MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma. BMC Cancer 2012; 12: 227 [PMID: 22681717 DOI: 10.1186/1471-2407-12-22 7]
76. Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, He Y, Dou KF. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumour Biol 2012; 33: 1455-1465 [PMID: 22528944 DOI: 10.1007/s13277-012-0396-1]
77. Chen L, Jiang M, Yuan W, Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg 2012; 25: 156-161 [PMID: 22583011 DOI: 10.3109/08941939.20]
78. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303 [PMID: 22213236 DOI: 10.1002/mc.21864]
79. Huang YH, Lin YH, Chi HC, Liao CH, Liao CJ, Wu SM, Chen CY, Tseng YH, Tsai CY, Lin SY, Hung YT, Wang CJ, Lin CD, Lin KH. Thyroid hormone regulation of miR-21 enhances migration and invasion of hepatoma. Cancer Res 2013; 73: 2505-2517 [PMID: 23442323 DOI: 10.1158/0008-5472]
80. Qi J, Wang J, Katayama H, Sen S, Liu SM. Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma. Neoplasma 2013; 60: 135-142 [PMID: 23259781]
81. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, Wang Z, Qiu S, Wang X, Yang G, Sun H, Tang Z, Wu Y, Zhu H, Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol 2011; 29: 4781-4788 [PMID: 22105822 DOI: 10.1200/JCO.2011.38.2697]
82. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, Huang L, Li H, Tan W, Wang C, Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011; 50: 136-142 [PMID: 21229610 DOI: 10.1002/mc.20712]
83. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011; 6: e23937 [PMID: 21886843 DOI: 10.1371/journal.pone.0023937]
84. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol 2012; 56: 167-175 [PMID: 21749846 DOI: 10.1016/j.jhep.2011.04.026]
85. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58: 234-239 [PMID: 23085648 DOI: 10.1016/j.jhep.2012.10.015]
86. van der Meer AJ, Farid WR, Sonneveld MJ, de Ruiter PE, Boonstra A, van Vuuren AJ, Verheij J, Hansen BE, de Knegt RJ, van der Laan LJ, Janssen HL. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 2013; 20: 158-166 [PMID: 23383654 DOI: 10.1111/jvh.12001]
87. Shigoka M, Tsuchida A, Matsudo T, Nagakawa Y, Saito H, Suzuki Y, Aoki T, Murakami Y, Toyoda H, Kumada T, Bartenschlager R, Kato N, Ikeda M, Takashina T, Tanaka M, Suzuki R, Oikawa K, Takanashi M, Kuroda M. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int 2010; 60: 351-357 [PMID: 20518884 DOI: 10.1111/j.1440-1827.2010.02526.x]
88. Li LM, Hu ZB, Zhou ZX, Chen X, Liu FY, Zhang JF, Shen HB, Zhang CY, Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBVpositive hepatocarcinoma. Cancer Res 2010; 70: 9798-9807 [PMID: 21098710 DOI: 10.1158/0008-5472.CAN-10-1001]
89. Liu WH, Yeh SH, Chen PJ. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta 2011; 1809: 678-685 [PMID: 21565290 DOI: 10.1016/j.bbagrm]
90. Hou W, Tian Q, Zheng J, Bonkovsky HL. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010; 51: 1494-1504 [PMID: 20127796 DOI: 10.1002/hep.23401]
91. Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012; 287: 9817-9826 [PMID: 22308024 DOI: 10.1074/jbc.M111.333534]
92. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
93. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010; 70: 5184-5193 [PMID: 20501828 DOI: 10.1158/0008-5472.CAN-10-0145]
94. Tan S, Li R, Ding K, Lobie PE, Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett 2011; 585: 2229-2234 [PMID: 21658389 DOI: 10.1016/j.febslet.2011.05.042]
95. Buurman R, Gürlevik E, Schäffer V, Eilers M, Sandbothe M, Kreipe H, Wilkens L, Schlegelberger B, Kühnel F, Skawran B. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 2012; 143: 811-20.e1-15 [PMID: 22641068 DOI: 10.1053/j.gastro.2012.05.033]
96. Sharma AD, Narain N, Händel EM, Iken M, Singhal N, Cathomen T, Manns MP, Schöler HR, Ott M, Cantz T. MicroRNA-221 regulates FAS-induced fulminant liver fail-ure. Hepatology 2011; 53: 1651-1661 [PMID: 21400558 DOI: 10.1002/hep.24243]
97. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS, Fisher PB, Sarkar D. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem 2012; 287: 13952-13958 [PMID: 22396537 DOI: 10.1074/jbc.M111.321646]
98. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012; 122: 2871-2883 [PMID: 22820288 DOI: 10.1172/JCI63539]
99. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012; 122: 2884-2897 [PMID: 22820290 DOI: 10.1172/JCI63455]
100. Ma L, Liu J, Shen J, Liu L, Wu J, Li W, Luo J, Chen Q, Qian C. Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther 2010; 9: 554-561 [PMID: 20150764]
101. Cheng J, Zhou L, Xie QF, Xie HY, Wei XY, Gao F, Xing CY, Xu X, Li LJ, Zheng SS. The impact of miR-34a on protein output in hepatocellular carcinoma HepG2 cells. Proteomics 2010; 10: 1557-1572 [PMID: 20186752 DOI: 10.1002/pmic.200900646]
102. Kim T, Veronese A, Pichiorri F, Lee TJ, Jeon YJ, Volinia S, Pineau P, Marchio A, Palatini J, Suh SS, Alder H, Liu CG, Dejean A, Croce CM. p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med 2011; 208: 875-883 [PMID: 21518799 DOI: 10.1084/jem.20110235]
103. Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer 2011; 30: 371-380 [PMID: 21627859]
104. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90 [PMID: 20693987 DOI: 10.1038/nature09284]
105. Wu K, Ding J, Chen C, Sun W, Ning BF, Wen W, Huang L, Han T, Yang W, Wang C, Li Z, Wu MC, Feng GS, Xie WF, Wang HY. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012; 56: 2255-2267 [PMID: 22898879 DOI: 10.1002/hep.26007]
106. Yuan K, Lian Z, Sun B, Clayton MM, Ng IO, Feitelson MA. Role of miR-148a in hepatitis B associated hepatocellular carcinoma. PLoS One 2012; 7: e35331 [PMID: 22496917 DOI: 10.1371/journal.pone.0035331]
107. Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, Cescon M, Ravaioli M, Croce CM, Bolondi L, Gramantieri L. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol 2012; 227: 275-285 [PMID: 22262409 DOI: 10.1002/path.3995]
108. Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011; 6: e19518 [PMID: 21573166 DOI: 10.1371/journal.pone.0019518]
109. Fang Y, Xue JL, Shen Q, Chen J, Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology 2012; 55: 1852-1862 [PMID: 22234835 DOI: 10.1002/hep.25576]
110. Shimizu S, Takehara T, Hikita H, Kodama T, Miyagi T, Hosui A, Tatsumi T, Ishida H, Noda T, Nagano H, Doki Y, Mori M, Hayashi N. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 2010; 52: 698-704 [PMID: 20347499 DOI: 10.1016/j.jhep.2009.12.024]
111. Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol 2013; 28: 565-575 [PMID: 22989374 DOI: 10.1111/j.1440-1746.2012.07271.x]
112. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2010; 51: 836-845 [PMID: 20041405 DOI: 10.1002/hep.23380]
113. Zhao A, Zeng Q, Xie X, Zhou J, Yue W, Li Y, Pei X. MicroRNA-125b induces cancer cell apoptosis through suppression of Bcl-2 expression. J Genet Genomics 2012; 39: 29-35 [PMID: 22293115 DOI: 10.1016/j.jgg.2011.12.003]
114. Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013; 32: 3071-3079 [PMID: 22824797 DOI: 10.1038/onc.2012.318]
115. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, Phelps MA, Papenfuss TL, Croce CM, Patel T, Schmittgen TD. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res 2011; 71: 7608-7616 [PMID: 22009537 DOI: 10.1158/0008-5472.CAN-11-1144]
116. Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M. Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 2012; 56: 1025-1033 [PMID: 22473819 DOI: 10.1002/hep.25747]
117. Hildebrandt-Eriksen ES, Aarup V, Persson R, Hansen HF, Munk ME, Ørum H. A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. Nucleic Acid Ther 2012; 22: 152-161 [PMID: 22545703 DOI: 10.1089/nat.2011.0332]
118. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]
119. Di Martino MT, Gullà A, Cantafio ME, Lionetti M, Leone E, Amodio N, Guzzi PH, Foresta U, Conforti F, Cannataro M, Neri A, Giordano A, Tagliaferri P, Tassone P. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013; 4: 242-255 [PMID: 23479461]
120. Lang Q, Ling C. MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA. Biochem Biophys Res Commun 2012; 426: 247-252 [PMID: 22940133 DOI: 10.1016/j.bbrc.2012.08.075]
121. Lindow M, Kauppinen S. Discovering the first microRNAtargeted drug. J Cell Biol 2012; 199: 407-412 [PMID: 23109665 DOI: 10.1083/jcb.201208082]
122. Ibrahim AF, Weirauch U, Thomas M, Grünweller A, Hartmann RK, Aigner A. MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res 2011; 71: 5214-5224 [PMID: 21690566 DOI: 10.1158/0008-5472.CAN-10-4645]
123. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev 2011; 25: 646-659 [PMID: 21406558 DOI: 10.1101/gad.2004211]
124. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011; 19: 232-243 [PMID: 21316602 DOI: 10.1016/j.ccr.2011.01.001]
125. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH, Lin JS. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene 2012; 31: 3357-3369 [PMID: 22056881 DOI: 10.1038/onc.2011.500]
126. Bader AG. miR-34 -a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 120 [PMID: 22783274]
127. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 2012; 72: 5576-5587 [PMID: 22964582 DOI: 10.1158/0008-5472. CAN-12-2001]
128. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012; 18: 6260-6270 [PMID: 23035210 DOI: 10.1158/1078-0432.CCR-12-1708]
129. Lou W, Chen Q, Ma L, Liu J, Yang Z, Shen J, Cui Y, Bian XW, Qian C. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med (Berl) 2013; 91: 715-725 [PMID: 23292172 DOI: 10.1007/s00109-012-0985-x]
130. Zhu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C, Zhuang SM. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 2012; 40: 4615-4625 [PMID: 22210897 DOI: 10.1093/nar/gkr1278]
131. Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, Doki Y, Mori M. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010; 103: 1617-1626 [PMID: 20978511 DOI: 10.1038/sj.bjc.6605958]
132. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST, Ghoshal K. TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 2010; 29: 1787-1797 [PMID: 20023698 DOI: 10.1038/onc.2009.468]
133. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 2009; 284: 32015-32027 [PMID: 19726678 DOI: 10.1074/jbc. M109.016774]
134. Lasa A, Garcia A, Alonso C, Millet P, Cornet M, Ramón y Cajal T, Baiget M, Barnadas A. Molecular detection of peripheral blood breast cancer mRNA transcripts as a surrogate biomarker for circulating tumor cells. PLoS One 2013; 8: e74079 [PMID: 24058517 DOI: 10.1371/journal.pone.0074079]
135. Devonshire AS, Sanders R, Wilkes TM, Taylor MS, Foy CA, Huggett JF. Application of next generation qPCR and sequencing platforms to mRNA biomarker analysis. Methods 2013; 59: 89-100 [PMID: 22841564 DOI: 10.1016/j.ymeth.2012.07.021]
136. Wang Y, Shen Z, Zhu Z, Han R, Huai M. Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC. Hepat Mon 2011; 11: 195-199 [PMID: 22087143]
137. Yin T, Cho SJ, Chen X. RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability. J Biol Chem 2013; 288: 23680-23686 [PMID: 23836903 DOI: 10.1074/jbc. M113.480186]